Skip to main content
SpringerLink
Log in

The Role of mTOR in Osteoclasts

  • Chapter
  • First Online:
Autophagy in Health and Disease

Part of the book series: Stem Cell Biology and Regenerative Medicine ((STEMCELL))

  • 667 Accesses

Abstract

Evolutionary conserved kinase mechanistic target of rapamycin (mTOR) is the signaling hub for cellular responses to nutrients, cytokines, growth hormones, and environmental stresses in all eukaryotic cells. Increased mTOR activity has been demonstrated in numerous diseases, such as cancer and autoimmune diseases. Due to its prominent role, mTOR inhibitors are being used and tested to treat a wide variety of conditions. Recent evidence suggests that regulation of mTOR activity and function is not universal and varies between the cells. Here we summarize the latest research on the role and regulation of mTOR in osteoclasts, the unique multinucleated bone-resorbing cells, focusing on the role of mTOR as part of the mTORC1 complex. Collectively, the results suggest that mTORC1 activity plays a double role in osteoclastogenesis: at the earlier stage, it is necessary for proliferation of the precursors, and, at the later stage, it is indispensable for cytoskeletal reorganization involved in the process of bone resorption. We also present evidence that in osteoclasts, mTOR protein levels and activity are regulated differently compared to other primary cells and cell lines. Due to this prominent role of mTOR in osteoclast formation and function, mTOR inhibitors could be used to treat numerous diseases that involve overactive osteoclasts, such as osteoporosis, inflammatory arthritis, Paget’s disease, and cancer-related osteolysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Crockett JC, et al. Bone remodelling at a glance. J Cell Sci. 2011;124(Pt 7):991–8.

    Article  CAS  Google Scholar 

  2. Teti A. Mechanisms of osteoclast-dependent bone formation. Bonekey Rep. 2013;2:449.

    Article  PubMed  Google Scholar 

  3. Ono T, Nakashima T. Recent advances in osteoclast biology. Histochem Cell Biol. 2018;149:325.

    Article  CAS  Google Scholar 

  4. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.

    Article  CAS  Google Scholar 

  5. Hsu H, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96(7):3540–5.

    Article  CAS  PubMed  Google Scholar 

  6. Wiktor-Jedrzejczak W, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A. 1990;87(12):4828–32.

    Article  CAS  PubMed  Google Scholar 

  7. Salo J, et al. Removal of osteoclast bone resorption products by transcytosis. Science. 1997;276(5310):270–3.

    Article  CAS  Google Scholar 

  8. Tondravi MM, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997;386(6620):81–4.

    Article  CAS  Google Scholar 

  9. Carey HA, et al. Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation. Bone Res. 2018;6:8.

    Article  PubMed  Google Scholar 

  10. Yagi M, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005;202(3):345–51.

    Article  CAS  PubMed  Google Scholar 

  11. Miyamoto H, et al. OC-STAMP and DC-STAMP cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res. 2012;27:1289.

    Article  CAS  Google Scholar 

  12. McDonald M, et al. Intravital imaging of osteoclasts in vivo reveals cellular recycling as a novel cell fate mechanism. J Bone Miner Res. 2017;32(Suppl 1):Abstrac #1109.

    Google Scholar 

  13. Clausen BE, et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8(4):265–77.

    Article  CAS  Google Scholar 

  14. Chiu WS, et al. Transgenic mice that express Cre recombinase in osteoclasts. Genesis. 2004;39(3):178–85.

    Article  CAS  Google Scholar 

  15. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.

    Article  CAS  PubMed  Google Scholar 

  16. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–9.

    Article  CAS  Google Scholar 

  17. Hara K, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177–89.

    Article  CAS  Google Scholar 

  18. Nojima H, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003;278(18):15461–4.

    Article  CAS  Google Scholar 

  19. Kim DH, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11(4):895–904.

    Article  CAS  Google Scholar 

  20. Peterson TR, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–86.

    Article  CAS  PubMed  Google Scholar 

  21. Sancak Y, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25(6):903–15.

    Article  CAS  Google Scholar 

  22. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013;126(Pt 8):1713–9.

    Article  CAS  PubMed  Google Scholar 

  23. Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol. 2013;203(4):563–74.

    Article  CAS  PubMed  Google Scholar 

  24. Meng D, Frank AR, Jewell JL. mTOR signaling in stem and progenitor cells. Development. 2018;145(1):pii: dev152595.

    Article  Google Scholar 

  25. Efeyan A, Zoncu R, Sabatini DM. Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med. 2012;18(9):524–33.

    Article  CAS  PubMed  Google Scholar 

  26. Manning BD, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10(1):151–62.

    Article  CAS  Google Scholar 

  27. Han S, et al. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal. 2008;20(6):1084–91.

    Article  CAS  PubMed  Google Scholar 

  28. Wolfson RL, Sabatini DM. The dawn of the age of amino acid sensors for the mTORC1 pathway. Cell Metab. 2017;26(2):301–9.

    Article  CAS  PubMed  Google Scholar 

  29. Sancak Y, et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell. 2010;141(2):290–303.

    Article  CAS  PubMed  Google Scholar 

  30. Zoncu R, et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science. 2011;334(6056):678–83.

    Article  CAS  PubMed  Google Scholar 

  31. Wang S, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015;347(6218):188–94.

    Article  CAS  PubMed  Google Scholar 

  32. Rebsamen M, et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 2015;519(7544):477–81.

    Article  CAS  PubMed  Google Scholar 

  33. Chantranupong L, et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell. 2016;165(1):153–64.

    Article  CAS  PubMed  Google Scholar 

  34. Saxton RA, et al. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science. 2016;351(6268):53–8.

    Article  CAS  Google Scholar 

  35. Wolfson RL, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016;351(6268):43–8.

    Article  CAS  Google Scholar 

  36. Shen HM, Mizushima N. At the end of the autophagic road: an emerging understanding of lysosomal functions in autophagy. Trends Biochem Sci. 2014;39(2):61–71.

    Article  CAS  Google Scholar 

  37. Halova L, et al. Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a novel mode of TOR inhibition. J Cell Biol. 2013;203(4):595–604.

    Article  CAS  PubMed  Google Scholar 

  38. Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12(3):169–82.

    Article  CAS  Google Scholar 

  39. Indo Y, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013;28(11):2392–9.

    Article  CAS  Google Scholar 

  40. Zhang Y, et al. mTORC1 inhibits NF-kappaB/NFATc1 signaling and prevents osteoclast precursor differentiation, in vitro and in mice. J Bone Miner Res. 2017;32(9):1829–40.

    Article  CAS  Google Scholar 

  41. Xu S, et al. TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42. Cell Death Differ. 2018;

    Google Scholar 

  42. Glantschnig H, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10(10):1165–77.

    Article  CAS  Google Scholar 

  43. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 2005;280(5):3583–9.

    Article  CAS  Google Scholar 

  44. Hussein O, et al. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett. 2012;314(2):176–84.

    Article  CAS  Google Scholar 

  45. Wu H, et al. Bone size and quality regulation: concerted actions of mTOR in mesenchymal stromal cells and osteoclasts. Stem Cell Rep. 2017;8(6):1600–16.

    Article  CAS  Google Scholar 

  46. Touaitahuata H, Blangy A, Vives V. Modulation of osteoclast differentiation and bone resorption by Rho GTPases. Small GTPases. 2014;5:e28119.

    Article  PubMed  Google Scholar 

  47. Dai Q, et al. Inactivation of regulatory-associated protein of mTOR (raptor)/mammalian target of rapamycin complex 1 (mTORC1) signaling in osteoclasts increases bone mass by inhibiting osteoclast differentiation in mice. J Biol Chem. 2017;292(1):196–204.

    Article  CAS  Google Scholar 

  48. Tiedemann K, et al. Regulation of osteoclast growth and fusion by mTOR/raptor and mTOR/rictor/Akt. Front Cell Dev Biol. 2017;5:54.

    Article  PubMed  Google Scholar 

  49. Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 1998;273(7):3963–6.

    Article  CAS  Google Scholar 

  50. Korolchuk VI, et al. Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol. 2011;13(4):453–60.

    Article  CAS  PubMed  Google Scholar 

  51. Puertollano R. mTOR and lysosome regulation. F1000Prime Rep. 2014;6:52.

    Article  PubMed  Google Scholar 

  52. Rabanal-Ruiz Y, Korolchuk VI. mTORC1 and Nutrient homeostasis: the central role of the lysosome. Int J Mol Sci. 2018;19(3):pii: E818.

    Article  Google Scholar 

  53. Sardiello M, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–7.

    Article  CAS  Google Scholar 

  54. Kawasaki-Nishi S, Nishi T, Forgac M. Arg-735 of the 100-kDa subunit a of the yeast V-ATPase is essential for proton translocation. Proc Natl Acad Sci U S A. 2001;98(22):12397–402.

    Article  CAS  PubMed  Google Scholar 

  55. Voronov I, et al. The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis. J Bone Miner Res. 2013;28(1):108–18.

    Article  CAS  Google Scholar 

  56. Ochotny N, et al. The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice. J Bone Miner Res. 2011;26(7):1484–93.

    Article  CAS  Google Scholar 

  57. Toyomura T, et al. Three subunit a isoforms of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem. 2000;275(12):8760–5.

    Article  CAS  Google Scholar 

  58. Manolson MF, et al. The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (>or=10 nuclei) and small (<or= nuclei) osteoclasts. J Biol Chem. 2003;278(49):49271–8.

    Article  CAS  Google Scholar 

  59. Ochotny N, et al. The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy. J Cell Biochem. 2013;114(12):2823–33.

    Article  CAS  Google Scholar 

  60. Johnson L, et al. V-ATPases containing a3 subunit play a direct role in enamel development in mice. J Cell Biochem. 2017;118(10):3328–40.

    Article  CAS  Google Scholar 

  61. Liu H, et al. Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. FASEB J. 2009;23(10):3383–92.

    Article  CAS  Google Scholar 

  62. Hu Y, et al. Lysosomal pH plays a key role in regulation of mTOR activity in osteoclasts. J Cell Biochem. 2016;117(2):413–25.

    Article  CAS  Google Scholar 

  63. Wang A, et al. Activity-independent targeting of mTOR to lysosomes in primary osteoclasts. Sci Rep. 2017;7(1):3005.

    Article  PubMed  Google Scholar 

  64. Bartolomeo R, et al. mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy. J Clin Invest. 2017;127(10):3717–29.

    Article  PubMed  Google Scholar 

  65. Newton PT, et al. Pharmacological inhibition of lysosomes activates the MTORC1 signaling pathway in chondrocytes in an autophagy-independent manner. Autophagy. 2015;11(9):1594–607.

    Article  CAS  PubMed  Google Scholar 

  66. Hwang JY, et al. Global ischemia induces lysosomal-mediated degradation of mTOR and activation of autophagy in hippocampal neurons destined to die. Cell Death Differ. 2017;24:317.

    Article  CAS  Google Scholar 

  67. Johnson DE, et al. The position of lysosomes within the cell determines their luminal pH. J Cell Biol. 2016;212(6):677–92.

    Article  CAS  PubMed  Google Scholar 

  68. Heuser J. Changes in lysosome shape and distribution correlated with changes in cytoplasmic pH. J Cell Biol. 1989;108(3):855–64.

    Article  CAS  Google Scholar 

  69. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Dentistry, University of Toronto, Toronto, ON, Canada

    Ralph A. Zirngibl & Irina Voronov

Authors
  1. Ralph A. Zirngibl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irina Voronov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irina Voronov .

Editor information

Editors and Affiliations

  1. Ottawa, ON, Canada

    Kursad Turksen

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zirngibl, R.A., Voronov, I. (2018). The Role of mTOR in Osteoclasts. In: Turksen, K. (eds) Autophagy in Health and Disease. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-98146-8_5

Download citation

Publish with us

Policies and ethics

Search

Navigation